Intraarterial Thrombolysis: Pros

Conference paper


Under favorable conditions the body itself is able to dissolve even extensive arterial thrombi spontaneously and completely. It does this with the help of the tissue activator (t-PA) which is produced from endothelial cells and acts physiologically at the site of its formation, which means it acts locally and not systemically. It can achieve this in 10%–15% of embolic occlusions in healthy arteries with a minimal amount of t-PA which never produces any systemic effect. In thrombotic occlusions in arteries with arteriosclerotic changes, however, spontaneous lysis occurs very rarely, probably because the ability to release t-PA is reduced. We have been able to assist this lysis for over 25 years by using streptokinase (SK) or urokinase (UK). Until 8 years ago these activators of fibrinolysis were administered almost exclusively systemically. Depending on the size of the thrombus, a standard dosage of 2.5 million units of these substances has to be administered daily for several days if necessary. Using an ultrahigh dosage of 9 million units over 6 h, the same dose is recommended the next day if necessary. The results have been encouraging where the indications were favorable but the risk of bleeding or provoking systemic embolism could not be reliably estimated even by paying careful attention to the many contraindications, so that this therapy could not be employed generally [7].


Thrombotic Occlusion Embolic Occlusion Cumulative Patency Intraarterial Thrombolysis Healthy Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Collen D (1987) Biological properties of plasminogen activators. In: Sobel BE, Collen D, Grossbard EB (eds) Tissue plasminogen activator in thrombolytic therapy. Dekker, New York, pp 3–24Google Scholar
  2. 2.
    Gross R (1964) Blutgerinnung und Fibrinolyse. Behring Inst Mitt 44: 1–16Google Scholar
  3. 3.
    Hess H, Mietaschk A, Ingrisch H (1980) Niedrig dosierte thrombolytische Therapie zur Wiederherstellung der Strombahn bei arteriellen Verschlüssen. Dtsch Med Wochenschr 105: 787–791PubMedCrossRefGoogle Scholar
  4. 4.
    Hess H, Ingrisch H, Mietaschk A, Rath H (1982) Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med 307: 1627–1630PubMedCrossRefGoogle Scholar
  5. 5.
    Hess H, Mietaschk A, Brückl R (1987) Peripheral arterial occlusions: a 6-year experience with local low-dose thrombolytic therapy. Radiology 163: 753–758PubMedGoogle Scholar
  6. 6.
    Hess H, Mietaschk A, Becker-Lienau C (1988) Fibrinolyse mit rt-PA bei peripheren arteriellen Verschlüssen. Klin Wochenschr 66 (Suppl XII): 135–136PubMedCrossRefGoogle Scholar
  7. 7.
    Martin M, Fiebach BJO (1985) Die Streptokinasebehandlung peripherer Arterien- und Venen-schlüsse unter besonderer Berücksichtigung der ultrahohen Dosierung. Huber, BernGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • H. Hess

There are no affiliations available

Personalised recommendations